Opendata, web and dolomites

ScleroTest SIGNED

A rapid and cost-effective point-of-care diagnostic kit able to predict treatment response for appropriate Multiple Sclerosis management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ScleroTest project word cloud

Explore the words cloud of the ScleroTest project. It provides you a very rough idea of what is the project "ScleroTest" about.

fast    annual    young    magnetic    added    poc    2026    incidence    fruitful    multiple    18    microbiota    58    therapeutic    sclerotest    successful    predictive    resonance    25    care    unmet    competition    point    15    finalize    quick    nervous    scalability    chronic    biotechnology    mainly    savings    issue    outcomes    avenues    bioithas    first    performance    people    pcr    accurate    opportunity    patient    health    launch    sclerosis    analyzing    socioeconomic    foresees    predicting    properly    worldwide    competitive    plus    24    implantation    clinical    company    absence    patients    financial    biomarker    adults    profit    business    cheaper    cagr    therapy    virus    globally    therapies    ca    acute    ms    routine    predict    prompt    commercial    autoimmune    neurologists    treatment    personalized    immunomodulatory    33    disease    perform    biomarkers    accumulated    10    diagnostic    cure    2022    feasibility    million    invasive    prevalence    ing    public    women    secure    technological    plan    profiling    gut    times    central    diseases    men    market    correct    substantial    medicine    net    lt    tool    jc    rapid    02    lack    alternatives    inflammatory   

Project "ScleroTest" data sheet

The following table provides information about the project.

Coordinator
BIOITHAS SL 

Organization address
address: C/ MAESTRO JOAQUIN ZAPATER 6
city: ONIL ALICANTE
postcode: 3430
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://www.bioithas.com/h2020-sclerotest-project/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOITHAS SL ES (ONIL ALICANTE) coordinator 50˙000.00

Map

 Project objective

Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system currently affecting about 2.5 million people worldwide (mainly young adults, three times more women than men). There is no cure and therapies do not properly work in all patients. Personalized medicine is needed but we lack predictive biomarkers for treatment response to secure prompt and early treatment and the best clinical outcomes for each patient. Thus, MS represents a major public health issue with a substantial socioeconomic impact (€15.5 B annual costs in Europe). Bioithas is a biotechnology company in the field of health developing new diagnostic and therapeutic targets for autoimmune and inflammatory diseases. In response to the unmet need, it is focused on developing the first-ever gut microbiota based biomarker for predicting MS treatment response. ScleroTest, a quick point-of-care (PoC) diagnostic tool, will allow immunomodulatory profiling of patients to predict treatment response. It is a non-invasive, accurate (PCR performance), rapid (results in <24 h) and cost-competitive test (€25 test, ca. 58 % cheaper than magnetic resonance and JC virus alternatives). ScleroTest implantation in routine practice will face current MS management problems resulting on added value for patients, neurologists and health systems by allowing fast and correct therapy choice, better clinical outcomes and cost-savings. ScleroTest scalability will also open new avenues for personalized therapy in other diseases. Due to ScleroTest´s cost-competitive features plus the absence of real competition, the increasing MS prevalence and incidence globally and the growing PoC market (CAGR 10%, €33 B by 2022), Bioithas foresees ScleroTest as a fruitful business opportunity (accumulated net profit ca. €18.02 M, 2022-2026). To secure the successful market launch, we will perform a feasibility study analyzing technological, commercial and financial aspects to finalize our business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCLEROTEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCLEROTEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More